1. Scrip
  2. >>Business

Roche Deals With Huge Gantenerumab Curiosity At H1 Update

Anti-Amyloid Beta Therapy Is In Phase III For Alzheimer's

 
• By Sten Stovall

Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.

Swiss Pharma Said Filing Decision Must Await GRADUATE Data Next Year • Source: Alamy

Roche Holding AG said its pharma division was "on the road to recovery" as it served up a strong second quarter sales performance driven by new growth drivers and laced with positive pipeline updates.

The Swiss pharma beat most market forecasts for the second quarter when presenting its half-year results on 22 July, propelled by new drugs that helped it offset erosion

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.